Authors: Mike Clements, Matthew Cato, Khuram W Chaudhary, Stacie Chvatal, Annie Delaunois, Parker Ellingson, Steve Fiene, Catherine Garrison, Mohamed Kreir, Norimasa Miyamoto, Katie Newman, Bumpei Noda, Kimberly L Rockley, Leandro Royer, Timothy J Shafer, Christopher Strock, Ikuro Suzuki, Anke M Tukker, Remco HS Westerink, Takashi Yoshinaga, and Louisa AK Zolkiewski
Axion BioSystems, Atlanta, GA, USA; GSK, Collegeville, PA, USA; Bristol-Myers Squibb, Lawrenceville, NJ, USA; UCB, Braine-l’Alleud, Belgium; J&J Innovative Medicine, Beerse, Belgium; Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan; Tohoku Institute of Technology, Miyagi, 982-8577, Japan; VitroVo, Miyagi, 982-8577, Japan; ApconiX Ltd, Macclesfield, SK10 4TG, UK; Shafer Neurotox Consulting, LLC, Durham, NC, USA; Cyprotex, Watertown, MA, USA; Purdue University, IN, USA; Utrecht University, The Netherlands
Presented by Mike Clements on July 10th, 2026 at ISSCR 2026 Annual Meeting
